Clinical trial · Interventional
Magnifying NBI for Occult NPC
Trans-oral Magnifying Endoscopy With Narrow Band Imaging for Screening of Nasopharyngeal Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Diagnosis of nasopharyngeal carcinoma (NPC) is currently made by trans-nasal endoscopy and biopsy. The small caliber endoscope provides only a limited view of the nasopharynx and may not be able to provide a thorough assessment of the nasopharynx. The investigators have developed a novel endoscopic approach to access the nasopharynx by using a trans-oral high definition endoscope with magnification and image enhancement function. In this cohort study, we aim to investigate the efficacy of diagnosing NPC by applying the novel technique in a high risk patient group with elevated plasma EBV DNA but with negative screening with conventional trans-nasal endoscopy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Trans-oral magnifying endoscopy with NBI | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Trans-oral magnifying endoscopy with NBI
- description
- Transoral magnifying endoscopy with High Definition Upper Endoscope with Narrow Band Imaging enhancement (Olympus GIF-H290Z)
- interventionNames
- Procedure: Trans-oral magnifying endoscopy with NBI
Primary outcomes (1)
- measure
- Rate of Newly diagnosed Nasopharyngeal cancer
- timeFrame
- 1 month
- description
- Newly diagnosed nasopharyngeal cancer with the novel endoscopic approach
Secondary outcomes (7)
- measure
- Rate of Adverse event - overall
- timeFrame
- 7 days
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male, age ≥ 18 years old 2. Positive result on plasma EBV-DNA analysis 3. No cancer identified on conventional investigations including nasoendoscopy and MRI Exclusion Criteria: 1. History of nasopharyngeal, oropharyngeal cancer 2. Patients on anticoagulation (Including warfarin and other direct oral anti-coagulants) 3. Bleeding tendency (International Normalized Ratio (INR) \> 1.5 or Platelet \< 50 x109/L) 4. Trismus, unable to pass oral endoscope 5. Allergic to local anaesthetic agents (Lignocaine) 6. Failure of vital organ (heart, lungs, liver, or kidneys) function 7. Other conditions deemed unsuitable for endoscopy 8. Refusal to participate, or inability to sign consent for study
References
Publications (0)
Data not yet available